TNSN03155A1 - Vaccination unidose avec mycoplasma hyopneumoniae - Google Patents

Vaccination unidose avec mycoplasma hyopneumoniae

Info

Publication number
TNSN03155A1
TNSN03155A1 TNPCT/IB2002/002121A TNSN03155A TNSN03155A1 TN SN03155 A1 TNSN03155 A1 TN SN03155A1 TN SN03155 A TNSN03155 A TN SN03155A TN SN03155 A1 TNSN03155 A1 TN SN03155A1
Authority
TN
Tunisia
Prior art keywords
vaccine
hyo
single dose
mycoplasma hyopneumoniae
dose vaccination
Prior art date
Application number
TNPCT/IB2002/002121A
Other languages
English (en)
Inventor
Robin Lee Keich
Lisa Grace Sabbadini
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN03155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN03155A1 publication Critical patent/TNSN03155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES METHODES POUR LE TRAITEMENT OU LA PREVENTION D'UNE MALADIE OU AFFECTION CHEZ UN ANIMAL, PROVOQUEE PAR UNE INFECTION PAR MYCOPLASMA HYOPNEUMONIAE (M.HYO) EN ADMINISTRANT A L'ANIMAL AGE D'APPROXIMATIVEMENT TROIS (3) A DIX (10) JOURS UNE DOSE UNIQUE D'UNE QUANTITE EFFICACE D'UN VACCIN A M.HYO. LE VACCIN A M. HYO PEUT ETRE UNE PREPARATION VIVANTE, INACTIVEE OU MODIFIEE, DE CELLULES ENTIERES OU PARTIELLES, UN VACCIN A SOUS-UNITE, OU UN VACCIN A ACIDE NUCLEIQUE OU VACCIN A ADN. LE VACCIN A M. HYO ADMINISTRE CONFORMEMENT A LA PRESENTE INVENTION PEUT ETRE SYNTHETISE OU PRODUIT PAR RECOMBINAISON.
TNPCT/IB2002/002121A 2001-07-02 2002-06-07 Vaccination unidose avec mycoplasma hyopneumoniae TNSN03155A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
TNSN03155A1 true TNSN03155A1 (fr) 2005-12-23

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/IB2002/002121A TNSN03155A1 (fr) 2001-07-02 2002-06-07 Vaccination unidose avec mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (fr)
EP (3) EP1474067B2 (fr)
JP (1) JP2005515162A (fr)
KR (1) KR20040030785A (fr)
CN (3) CN101524532B (fr)
AP (1) AP2003002937A0 (fr)
AR (1) AR034678A1 (fr)
AT (1) ATE412426T2 (fr)
AU (1) AU2002309109B2 (fr)
BG (1) BG66481B1 (fr)
BR (1) BR0210804A (fr)
CA (1) CA2451626C (fr)
CY (1) CY1108749T1 (fr)
CZ (1) CZ305781B6 (fr)
DE (1) DE60229666D1 (fr)
DK (3) DK2027873T3 (fr)
DO (1) DOP2002000431A (fr)
EA (1) EA009901B1 (fr)
ES (3) ES2312580T5 (fr)
GT (1) GT200200138A (fr)
HK (1) HK1207584A1 (fr)
HR (1) HRP20031079A2 (fr)
HU (1) HU230246B1 (fr)
IL (1) IL159349A0 (fr)
IS (1) IS7076A (fr)
MA (1) MA27047A1 (fr)
MX (1) MXPA03011599A (fr)
NO (1) NO342654B1 (fr)
NZ (1) NZ530106A (fr)
OA (1) OA12638A (fr)
PA (1) PA8549701A1 (fr)
PE (1) PE20030285A1 (fr)
PL (1) PL209773B1 (fr)
PT (3) PT1474067E (fr)
SK (1) SK288010B6 (fr)
TN (1) TNSN03155A1 (fr)
TW (1) TWI329514B (fr)
UA (1) UA78707C2 (fr)
UY (1) UY27366A1 (fr)
WO (1) WO2003003941A2 (fr)
YU (1) YU102203A (fr)
ZA (1) ZA200309698B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (fr) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Vaccins multisouches a base de mycoplasma hyopneumoniae
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP2275132B1 (fr) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Composés immunogénique multivalent de PCV2 et leurs méthodes de préparation
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP1991262A4 (fr) * 2006-03-03 2009-11-04 Merial Ltd Vaccin contre le mycoplasma hyopneumoniae
EP2099927A4 (fr) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Procedes de reduction des flambees des maladies associees au circovirus porcin
EP2859900A1 (fr) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Procédé efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
BRPI0721083A2 (pt) 2006-12-15 2014-02-25 Boehringer Ingelheim Vetmed Tratamento de porcos com antígeno de pcv2
EP1941903A1 (fr) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN104043116A (zh) * 2007-11-06 2014-09-17 硕腾W有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
JP5613061B2 (ja) * 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
WO2009156960A2 (fr) * 2008-06-27 2009-12-30 Pfizer Inc. Nouvelles compositions d'adjuvants
WO2010140377A1 (fr) 2009-06-04 2010-12-09 独立行政法人産業技術総合研究所 Vaccin contre une infection par un mycoplasme
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
DK2569007T3 (en) 2010-05-11 2016-01-25 Intervet Int Bv VACCINE AGAINST Mycoplasma hyopneumoniae SUITABLE FOR ADMINISTRATION IN PRESENCE OF maternally derived antibodies
RU2581922C2 (ru) * 2010-07-26 2016-04-20 Кью Байолоджикс Инк. Иммуногенные противовоспалительные композиции
EP2609428B1 (fr) * 2010-08-27 2016-02-10 Intervet International B.V. Test d'activité biologique destiné à des formulations de vaccin
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
UA115053C2 (uk) 2012-03-07 2017-09-11 Сева Санте Анімаль Композиція, що містить антиген і ліпополісахарид у формі масло-в-воді, та спосіб її використання (варіанти)
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
DK2938747T3 (da) 2012-12-28 2019-08-05 Boehringer Ingelheim Vetmedica Gmbh Fremgangsmåde til fremstilling af en mycoplasma vaccine
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
KR101831318B1 (ko) * 2013-02-05 2018-02-22 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 항-마이코플라즈마 에스피피. 아단위 백신
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
UA121200C2 (uk) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US9951109B2 (en) * 2013-11-21 2018-04-24 Agricultural Technology Research Institute Composition for preventing Mycoplasma spp. infection
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
EP4248992A3 (fr) 2015-01-16 2023-12-27 Zoetis Services LLC Vaccin contre la fièvre aphteuse
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
KR101846478B1 (ko) * 2016-08-12 2018-04-06 주식회사 이노백 재조합 단백질을 포함하는 돼지 마이코플라즈마 감염 예방용 백신 조성물
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283840A3 (fr) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Antigène de mycoplasma hyopneumoniae et ses utilisations
US5252328A (en) 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
DE3881993T2 (de) 1987-09-18 1993-09-30 Akzo Nv Mycoplasma-Impfstoff.
AU7682091A (en) 1990-04-02 1991-10-30 Synergen, Inc. Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
ATE160699T1 (de) 1990-05-29 1997-12-15 American Cyanamid Co Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (fr) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. ADN's encodant les antiqèues superficiels de mycoplasma hyopneumonique, fragments d'ADN pour les amorces, peptides recombinants antigéniques et méthode diagnostique de pneumonie mycoplasmale de porc les utilisant
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
PT839050E (pt) 1992-09-28 2004-11-30 Wyeth Corp Metodo de melhorar respostas imunes mediadas por celulas
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (fr) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. CARACTERISATION D'ADHESINES DE $i(MYCOPLASMA HYOPNEUMONIAE)
WO1995030437A1 (fr) 1994-05-10 1995-11-16 American Home Products Corporation Vaccin vivant modifie, ameliore, contre le virus respiratoire syncytial bovin (vrsb)
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
PL332540A1 (en) 1996-09-30 1999-09-13 Embrex Method of inducing active immunity using a vaccine conjugate
EP0846468B1 (fr) 1996-12-05 2004-06-09 Akzo Nobel N.V. Mycoplasma synoviae non virulent et vaccin de celui-ci
PL341797A1 (en) 1997-11-26 2001-05-07 Univ Iowa State Res Found Inc Recombined vaccine against mycoplasma hyopneumoniae
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
MA27047A1 (fr) 2004-12-20
NO20035762L (no) 2004-02-02
JP2005515162A (ja) 2005-05-26
PA8549701A1 (es) 2003-01-24
HUP0400434A2 (en) 2007-08-28
ATE412426T2 (de) 2008-11-15
UY27366A1 (es) 2003-04-30
HK1207584A1 (en) 2016-02-05
GT200200138A (es) 2003-05-15
US20030109473A1 (en) 2003-06-12
USRE44399E1 (en) 2013-07-30
DK2842569T3 (da) 2019-05-20
CA2451626A1 (fr) 2003-01-16
NO342654B1 (no) 2018-06-25
DK1474067T3 (da) 2008-12-08
BG66481B1 (bg) 2015-02-27
NZ530106A (en) 2007-06-29
AP2003002937A0 (en) 2003-12-31
CN1551781B (zh) 2013-01-02
CN102872456B (zh) 2016-01-20
EP2842569B1 (fr) 2019-04-10
EP2027873B1 (fr) 2015-09-09
ZA200309698B (en) 2014-04-30
US6846477B2 (en) 2005-01-25
PL209773B1 (pl) 2011-10-31
HK1180224A1 (zh) 2013-10-18
EP1474067A2 (fr) 2004-11-10
IL159349A0 (en) 2004-06-01
PE20030285A1 (es) 2003-03-27
EP2842569A1 (fr) 2015-03-04
SK288010B6 (sk) 2012-10-02
HK1134900A1 (zh) 2010-05-20
US20050013823A1 (en) 2005-01-20
MXPA03011599A (es) 2005-03-07
IS7076A (is) 2003-12-15
DK2027873T3 (en) 2015-11-09
PT2027873E (pt) 2015-11-03
HK1068250A1 (en) 2005-04-29
CN101524532B (zh) 2014-03-19
PT1474067E (pt) 2008-11-14
ES2312580T3 (es) 2009-03-01
EA009901B1 (ru) 2008-04-28
WO2003003941A2 (fr) 2003-01-16
EP2027873A1 (fr) 2009-02-25
DK1474067T4 (en) 2017-10-16
CZ305781B6 (cs) 2016-03-16
DE60229666D1 (de) 2008-12-11
ES2729579T3 (es) 2019-11-04
CN101524532A (zh) 2009-09-09
ES2550458T3 (es) 2015-11-10
TWI329514B (en) 2010-09-01
EP1474067B2 (fr) 2017-08-16
CZ20033466A3 (cs) 2005-06-15
CA2451626C (fr) 2011-05-31
EP1474067B1 (fr) 2008-10-29
BG108546A (bg) 2005-02-28
PT2842569T (pt) 2019-06-17
EP2027873B8 (fr) 2015-11-11
EP1474067A4 (fr) 2005-08-10
BR0210804A (pt) 2005-05-03
CY1108749T1 (el) 2014-04-09
SK15792003A3 (sk) 2005-09-08
PL373367A1 (en) 2005-08-22
UA78707C2 (en) 2007-04-25
ES2312580T5 (es) 2017-12-11
WO2003003941A3 (fr) 2004-07-29
CN1551781A (zh) 2004-12-01
HRP20031079A2 (en) 2005-10-31
AR034678A1 (es) 2004-03-03
OA12638A (en) 2006-06-15
HU230246B1 (hu) 2015-11-30
KR20040030785A (ko) 2004-04-09
EA200301323A1 (ru) 2005-06-30
AU2002309109B2 (en) 2007-12-13
YU102203A (sh) 2006-05-25
DOP2002000431A (es) 2003-01-15
CN102872456A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
TNSN03154A1 (fr) Vaccin a mycoplasma bovis et methodes pour reduire la pneumonie chez des animaux.
WO2003003941A3 (fr) Vaccin monodose a base de mycoplasma hyopneumoniae
RU2246944C2 (ru) Композиции, предназначенные для улучшения фертильности
MXPA02012201A (es) Metodos y composicion para vacunacion oral.
MA27388A1 (fr) Vaccin pour des infections du systeme respiratoire et du systeme reproducteur chez les bovins
BR0211049A (pt) Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
JP2005534752A5 (fr)
KR20090053967A (ko) 웨스트 나일 백신
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
BR0209017A (pt) Novas piridil benzazepina carboxamidas tricìclicas e antagonistas receptores de ocitocina tocolìticos derivados das mesmas
JP2024174906A (ja) 運動系の疾患の治療のために有用な組成物
RU2008105348A (ru) Вакцина на основе lawsonia и способы ее применения
US20100291115A1 (en) Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof
RU2093177C1 (ru) Препарат "дина" для лечения и профилактики заболеваний млекопитающих, птиц и рептилий
RU2232501C2 (ru) Способ повышения естественной резистентности животных
RU2258501C2 (ru) Способ применения этидия бромистого для лечения пироплазмоза лошадей
FR2507479A1 (fr) Vaccin contre les infections chlamydiennes des animaux d'elevage
JP2004210769A (ja) 魚類冷水病ワクチン
RU2165757C1 (ru) Лечебно-профилактическое средство для молодняка сельскохозяйственных животных и птицы
RU2146532C1 (ru) Способ лечения и профилактики трихофитии и микроспории пушных зверей и мелких плотоядных животных
RU2204899C2 (ru) Способ повышения воспроизводительной способности ремонтных свинок
RU2004118613A (ru) Способ профилактики и лечения дирофиляриоза собак
Getachew et al. Treatment of epizootic lymphangitis in cart horses through participatory method.
Lawson et al. ERA strain rabies vaccine: oral vaccination of nonhuman primates
WO2004103408A2 (fr) Composition vaccinale comprenant du phosphate de fer a titre d’adjuvant vaccinal